Driehaus Capital Management’s PTC Therapeutics PTCT Stock Holding History

Driehaus Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117M	Buy	1,440,107 +424,335	+42%	+$30.6M	0.68%	33
2026 Q1	$69.2M	Sell	1,015,772 -120,416	-11%	-$8.53M	0.51%	54
2025 Q4	$86.3M	Buy	1,136,188 +4,439	+0.4%	+$323K	0.59%	45
2025 Q3	$69.5M	Buy	1,131,749 +72,723	+7%	+$3.79M	0.5%	63
2025 Q2	$51.7M	Sell	1,059,026 -453,619	-30%	-$21.5M	0.41%	75
2025 Q1	$77.1M	Buy	1,512,645 +471,586	+45%	+$23.5M	0.74%	33
2024 Q4	$47M	Buy	+1,041,059	New	+$44.6M	0.39%	92
2015 Q2	–	Sell	-12,329	Closed	-$750K	–	567
2015 Q1	$750K	Buy	+12,329	New	+$752K	0.03%	430

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Driehaus Capital Management's PTCT Position: Q2 2026 in Review

Driehaus Capital Management increased its PTC Therapeutics (PTCT) stake by 42% in Q2 2026, buying an estimated $30.6M and bringing the position to 1,440,107 shares worth $117M. The position accounts for 0.68% of the portfolio, ranked #33.

Driehaus Capital Management first reported a position in PTCT in Q1 2015 and has held it in 8 quarters since. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Driehaus Capital Management held 1,440,107 shares of PTC Therapeutics worth $117M as of Q2 2026.
Driehaus Capital Management bought 424,335 PTC Therapeutics shares in Q2 2026, an estimated $30.6M.
PTC Therapeutics made up 0.68% of Driehaus Capital Management's portfolio in Q2 2026, its #33 holding.
Driehaus Capital Management first reported a position in PTC Therapeutics in Q1 2015 and has held it in 8 quarters since.
383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Driehaus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.